 Shares of Werewolf Therapeutics Inc. jumped 10.8 in premarket trading on Thursday after the company announced a licensing deal with Jazz Pharmaceuticals Plc worth up to 1.2 billion. Jazz now has exclusive development and commercialization rights to Werewolfs preclinical immuno-oncology candidate and plans to submit the molecule for Food and Drug Administration approval in 2023. 